These studies, therefore, do not show the possible impact of comorbidities on the general condition of SMA patients and consequently on their QoL together with suggested associations with SMN protein deficiency. This evidence concerns the gene SMN2 and hereditary thrombophilia due to congenital protein S deficiency.